Diabetic is a worldwide health issue and diabetic kidney disease is a dreaded complication of the disease. Drugs that can impair intestinal absorption of advanced glycation end products (AGE) can improve glycemic control and lipid profile. Sevelamer is a calcium free phosphate binder and has postulated to have a role in prevention of absorption of age. The aim of the study was to compare the mean change HbA1c and lipid profile in diabetic kidney disease by selvelamer vs calcium carbonate. The mean of the patient was 58.53 years. Sevelamer showed a mean decrease in HbA1c and lipid profile as compared to calcium carbonate (-0.57 + 45, -8.35 ± 9.006, -1.40 ± 7.07, -4.20 ± 4.26, vs -0.08 ± 0.21, 0.10 ± 2.51, 0.62 ± 1.03, 1.00 ± 1.55). However there was a mean rise in C-reactive protein. We concluded that sevelamer caused greater mean decrease that in HBA1c and lipid profile as compared to calcium carbonate but failed to decrease C- reactive protein.
Keywords: Advanced Glycation end Products (AGE), Diabetic Nephropathy, Glomerular Filtration Rate (GFR), Hyperfiltration, Nephrotic Syndrome, End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), UK Prospective Diabetic Study (UKPDS), HbA1C, C – reactive protein (CRP), High density Lipoprotein (HDL), Low Density Lipoprotein (LDL), Chronic Renal insufficiency